EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice

Marin Kunimoto, Yasutomo Imai, Masako Matsutani, Minori Nakatani‐Kusakabe, Makoto Nagai, Masaru Natsuaki, Kiyofumi Yamanishi, Nobuo Kanazawa

Journal of Cutaneous Immunology and Allergy · 2022-04 · 5 (2) · 69-71

DOI: 10.1002/cia2.12212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Immunology and Allergy, online erschienen am 27.09.2021. Verfasst von Marin Kunimoto und 7 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kunimoto, M., Imai, Y., Matsutani, M., Nakatani‐Kusakabe, M., Nagai, M., Natsuaki, M., Yamanishi, K., & Kanazawa, N. (2022). Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice. Journal of Cutaneous Immunology and Allergy, 5(2), 69-71. https://doi.org/10.1002/cia2.12212

Vancouver

Kunimoto M, Imai Y, Matsutani M, Nakatani‐Kusakabe M, Nagai M, Natsuaki M, et al. Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice. Journal of Cutaneous Immunology and Allergy. 2022;5(2):69-71. doi:10.1002/cia2.12212

BibTeX
@article{Kunimoto2022,
  author = {Kunimoto, Marin and Imai, Yasutomo and Matsutani, Masako and Nakatani‐Kusakabe, Minori and Nagai, Makoto and Natsuaki, Masaru and Yamanishi, Kiyofumi and Kanazawa, Nobuo},
  title = {Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice},
  journal = {Journal of Cutaneous Immunology and Allergy},
  year = {2022},
  volume = {5},
  number = {2},
  pages = {69--71},
  doi = {10.1002/cia2.12212}
}
Kostenlos starten →